SecBot SecBot

TVRD

Tvardi Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001346830 Biotech & Drug Discovery
$0.8653 +0.02 (+2.77%)
Oct 27 4:00 PM ET · prev $0.8420
Market cap
$12.5M
Nano cap
Consensus
Buy
80% Buy or better · 15 analysts
Median target
$10.00
+1056% · range $3.00–14.00
Next earnings
Nov 12
in 16 days · EPS est. −$0.57
1 year
−81.7%
from $4.72 · Oct 28
30 days
−34.9%
from $1.33
52-week range
$0.8420–5.00
−83% from high · low Oct 26
Avg volume 20D
154.7K
shares / day
Short interest
375.9K
≈2.8% of shares · +67.5%
Days to cover
2.2
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read MIXED 4 reports · 90 days
Balance 1 bearish · 1 bullish · 2 mixed oldest → newest, height = score
Avg score ·High conf. 1/4 ·Next Earnings date, Nov 12, 2026
Strongest MIXED Tvardi Therapeutics reported Q2 2026 EPS of $(0.69), a 6.2% miss vs consensus of $(0.65), with no revenue…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBEARISH

    Q2 2026: 6 added (0 new), 12 trimmed or exited.

  • AnalystsBULLISH

    12 of 15 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.537 → −$0.571 over 90 days. 2 up, 0 down in 30 days.

  • Short sellersBUILDING

    Short interest +67.5% to 375.9K shares. 2.2 days to cover, ≈2.8% of shares.

  • TrendDOWNTREND

    40% below its 50-day average. New closing low $0.8420 on Oct 26.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGDOUBLED111,133$211.2K
BlackRock, Inc.NEAR_EXIT95,478$181.4K
GEODE CAPITAL MANAGEMENT, LLCTRIM90,350$171.7K
Russell Investments Group, Ltd.ADD43,228$82.1K
STATE STREET CORPTRIM33,900$64.4K
NORTHERN TRUST CORPTRIM21,836$41.5K
Arax Advisory PartnersADD11,003$20.9K
PNC FINANCIAL SERVICES GROUP, INC.DOUBLED3,518$6.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

15 analysts
Buy 80% rate it Buy or better
Strong Buy4Buy8Hold2Sell1Strong Sell0
12-month targets · 9 analysts

Price is below the lowest target. Median implies +1056%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Oct 20, 2026Chardan Capital
INITIATE
INITIATEBuy
Jul 30, 2026BTIG
MAINTAIN
MAINTAINBuy
Jul 8, 2026Raymond James
UPGRADE
UPGRADEOutperform
Jul 7, 2026BTIG
REITERATE
REITERATEBuy
Jun 8, 2026HC Wainwright & Co.
INITIATE
INITIATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jun 9, 2026
Shiff Susan Ph.D.
Director
AWARD6,000 sh
Jun 9, 2026
Smith Cynthia
Director
AWARD6,000 sh
Jan 29, 2026
O'Brien Stephen Paul
Principal Accounting Officer
AWARD15,000 sh
Jan 29, 2026
Alibhai Imran Nizamudin
Chief Executive Officer
AWARD115,000 sh
Jan 29, 2026
Conn Avi Daniel
Chief Financial Officer
AWARD45,000 sh
Jan 29, 2026
Kauh John Saewook M.D.
Chief Medical Officer
AWARD45,000 sh

Earnings setup

Estimates
Nov 12
reports in 16 days
−$0.57
EPS estimate, this quarter
−6%
estimate change, 90 days
2↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.57-$1.06–-$0.28+2.6%$0.00
Next Q-$0.43-$0.85–-$0.13+12.0%$0.00
Current FY-$2.23-$3.02–-$1.60+3.1%$0.00
Next FY-$2.18-$4.52–-$0.51+2.4%$0.00

Short side

FINRA· Oct 15, 2026
375,939
shares short
+67.5%
vs prior settlement
2.2
days to cover
≈2.8%
of shares outstanding
Trading halts
Jul 8, 2026Volatility PauseResumed
Jul 8, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 26, 2026 Other
Tvardi Therapeutics to Participate in Upcoming Investor Events
HOUSTON, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a cl
Aug 21, 2026 SEC
In Q2 2026, 9 institutional sellers reduced TVRD holdings by ~$1.85M, led by BlackRock (near-exit, -$1.05M), Geode…
INST-CLUSTER — Impact 4/10
Aug 14, 2026 SEC
Tvardi Therapeutics reported Q2 2026 EPS of $(0.69), a 6.2% miss vs consensus of $(0.65), with no revenue. The company…
8-K — Impact 5/10
Aug 14, 2026 SEC
Tvardi Therapeutics reported Q2 2026 EPS of -$0.73, a 15.6% miss vs consensus of -$0.63, with no revenue. Pipeline…
PRESS-RELEASE — Impact 5/10
Jun 30, 2026 Inst.
UBS Group AG — DOUBLED
111,133 shares ($211.2K)
Jun 30, 2026 Inst.
BlackRock, Inc. — NEAR_EXIT
95,478 shares ($181.4K)
Jun 9, 2026 Insider
Shiff Susan Ph.D. was granted 6,000 shares
Director
Jun 9, 2026 Insider
Smith Cynthia was granted 6,000 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 12, 2026
Earnings date
TVRD Q3 2026 Earnings Scheduled — 2026-11-12
Recent
Aug 26, 2026
Press release
Tvardi Therapeutics to Participate in Upcoming Investor Events
HOUSTON, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused…
Aug 14, 2026
Earnings
Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and…
Aug 13, 2026
Earnings date
TVRD Q2 2026 Earnings Scheduled — 2026-08-13
Aug 13, 2026
Clinical Trial
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
Phase 2 · COMPLETED
Aug 12, 2026
Earnings date
TVRD Q2 2026 Earnings Scheduled — 2026-08-12

SecBot reports

10 filings · 2 bullish · 3 bearish · 3 mixed · 2 neutral
All TVRD filing & press-release reports (10)